Burden of de novo malignancy in the liver transplant recipient - Wikidata - awgldk - TriplyDB

Burden of de novo malignancy in the liver transplant recipient

Burden of de novo malignancy in the liver transplant recipient

http://www.wikidata.org/entity/Q26859216

about

Neoplastic disease after liver transplantation: Focus on de novo neoplasms Liver transplantation: immunosuppression and oncology Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis Betel quid chewing leads to the development of unique de novo malignancies in liver transplant recipients, a retrospective single center study in Taiwan.Donor transmitted and de novo cancer after liver transplantation.Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms.Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats.Post-transplant malignancy in liver transplantation: a single center experience Liver transplantation in alcoholic liver disease current status and controversies.Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX).Long-term survival after liver transplantation for alcoholic liver disease.Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients.Pulmonary nodules in liver transplant candidates with hepatocellular carcinoma: Imaging characteristics and clinical outcomes.Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study.Keys to long-term care of the liver transplant recipient.28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines.Cervical human papillomavirus infection in the early postoperative period after liver transplantation: Prevalence, risk factors, and concordance with anal infections.Skin cancer in immunosuppressed transplant patients: Vigilance matters.Impact of non-anastomotic biliary strictures after liver transplantation on healthcare consumption, use of ionizing radiation and infectious events.The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China.Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo Head and neck and esophageal cancers after liver transplant: results from a multicenter cohort study. Italy, 1997-2010.Extensive multifocal branch duct IPMN of the pancreas after liver transplantation: is surgery justified?De novo malignant disease after liver transplantation? Risk and surveillance strategies.Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.Negative outcomes after liver transplantation in patients with alcoholic liver disease beyond the fifth post-transplant year.Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases.Decreasing incidence of cancer after liver transplantation-A Nordic population-based study over 3 decades.ACG Clinical Guideline: Alcoholic Liver Disease.Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.Fairly rare de novo inflammatory pseudotumor in a graft after living donor liver transplantation.Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes.

P2860

Q26798306-62A91AA0-B2E1-40EA-9BEE-E40861CDC5FE Q26827252-B17B3137-9E8A-42AE-BF74-2C56893897DE Q27025406-9CF7F827-E76E-4506-A4EA-B255D4198CE2 Q33595456-D9297C30-BF9E-4693-A3D1-EA3C85FDB244 Q33661124-57E5E43E-4998-4671-A19D-EA350E72A5F5 Q35067692-2CFD561A-1266-40FE-8902-C6B80BE68A3D Q36141134-86BF3E84-041B-4FC9-B325-7D112AFAF8B4 Q36154140-0297AF9E-5FBB-4A0C-AEE4-E1DC79A5187A Q37203525-F8EAF712-DA5D-45A2-BB0D-EDBD89DD1E39 Q37314134-587262B4-E76D-4288-99E2-B21A923AAB6E Q37439878-9403E8E8-E423-4557-B865-C185015D570B Q37696382-756B54AC-75B4-44F9-83E4-C3D07B60DF12 Q38407364-D5CD4BD1-9D09-4269-9FF0-87C6B7D707F3 Q38418542-38F200DB-0B46-4C68-AFC6-48D8FE2B38BC Q38605687-8618AB88-5B20-41C5-A48F-FDFBDD69BAC9 Q38738530-863CC965-177E-438E-B9C6-078343EACD43 Q38941149-03597746-348D-40B4-8C11-A1107EE31067 Q39091662-64CEC536-C489-4CEA-A75B-D769D3066B7B Q39364043-45DC8A87-9676-4383-AA89-CD2FA3CEBDFE Q40361626-BA8213AA-F0A7-43EC-ADF2-69F9A87D66AE Q40365638-366F53D6-6F59-4613-BB11-3225CBD384A3 Q41285493-60387042-2386-4FD9-9131-317292E68675 Q41426945-25DDED82-77DB-4751-B1AA-8A50D13480B5 Q43201553-0FB3F2D0-7880-471F-BB21-304FFD7B60B1 Q43857210-8DE86116-445D-4864-B7AE-1C53510DD8A0 Q44398159-1E62E631-5891-453D-A035-048AFE261E9C Q45090451-2A50D5F7-02F5-45BB-A91A-7BBC513A7260 Q46957206-714C260B-9C23-489C-BCDF-5D44A4634105 Q47688116-D0308268-D1EB-4ABE-84D7-526CF870C2A5 Q48536649-87C1AB1B-EB3C-41EB-BB97-96A603C91A5E Q51273202-0CD7D10D-DA7B-4641-95C4-91C758A10CAE Q53082236-BB10E5AF-D0CA-4239-BDCA-27EC045D98E5 Q54967602-67DE8D3E-B212-4C99-97BD-5FF5D8B62C9A

P2860

Burden of de novo malignancy in the liver transplant recipient

http://www.wikidata.org/entity/Q26859216

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Burden of de novo malignancy in the liver transplant recipient

@ast

Burden of de novo malignancy in the liver transplant recipient

@en

Burden of de novo malignancy in the liver transplant recipient

@nl

type

label

Burden of de novo malignancy in the liver transplant recipient

@ast

Burden of de novo malignancy in the liver transplant recipient

@en

Burden of de novo malignancy in the liver transplant recipient

@nl

prefLabel

Burden of de novo malignancy in the liver transplant recipient

@ast

Burden of de novo malignancy in the liver transplant recipient

@en

Burden of de novo malignancy in the liver transplant recipient

@nl

P1433

Q26859216-D0549449-0E32-43C1-9D30-D6451A11267D

P1476

Q26859216-1A17504A-76B8-426F-9C99-4815ED0F2E79

P2093

Q26859216-80FBC0FE-5C3F-4CC4-9073-10E5A522B78B

Q26859216-D0E91137-D685-4F57-BB18-FCA9B5BC32A1

P2860

Q26859216-00641A8B-A3AA-4AD7-AB4F-0AD2638F0E7D

Q26859216-0591B42C-BCBE-406C-AD33-D9B4C0F30675

Q26859216-094B5DE4-C56F-4D96-B6B0-0E9FA2F323F9

Q26859216-0AC1B12D-E085-4C42-999A-364E54979CB7

Q26859216-14796E80-10DE-4C44-B492-D527F2AEE2E6

Q26859216-168B85AC-8BFF-45D5-91D5-7F7509979C18

Q26859216-1B9A741E-B94F-4D80-BDD9-BE158959E081

Q26859216-1F8CCDC0-2F6D-48FA-A1FF-6D11671FE430

Q26859216-2173C7BF-939F-4022-85E4-0026ACF3F130

Q26859216-24D445A8-CCE8-4D80-89FB-C1F1D6F3DD3C

P304

Q26859216-12E35AE1-84C6-4387-81D2-55BB741CF329

P31

Q26859216-2C337001-7E50-441A-B8DD-320A0C127625

P3181

Q26859216-52433E12-C4D9-4E42-8186-FCBFA35CBC0A

P356

Q26859216-9DC5EAE0-5057-4544-A682-42C937C1D2A7

P407

Q26859216-7B4350E6-BFB3-468F-8678-707E94A960C8

P433

Q26859216-15E1ADFE-9BB1-4A80-8003-98D3FB13ACC5

P478

Q26859216-A2B06A04-3E45-4EC9-BF96-57AA3AF24D78

P577

Q26859216-524C9CE6-AAB1-4D3B-97A0-B67155DBDF8F

P5875

Q26859216-DA9FE6A5-F23A-4BFF-9BB4-59C8588DD29B

P698

Q26859216-049092B0-FE14-425A-99DD-599C772B1CFC

P3181

P356

P1433

Liver Transplantation

P1476

Burden of de novo malignancy in the liver transplant recipient

@en

P2093

Kymberly D. Watt

http://www.w3.org/2001/XMLSchema#string

Natasha Chandok

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

Azathioprine and UVA light generate mutagenic oxidative DNA damage

Preventable exposures associated with human cancers

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.

Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data.

Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.

Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study

P304

1277-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3396947

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/LT.23531

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230658847

http://www.w3.org/2001/XMLSchema#string

P698

22887956

http://www.w3.org/2001/XMLSchema#string